Incyte advances multiple early-phase cancer trials with potential therapeutic breakthroughs, highlighting their strategic focus on oncology and rare diseases.
Boeing's Q3 loss and 777X delay contrasted with Airbus' strong quarter, highlighting the industry's uneven recovery.
Incyte advances multiple early-phase cancer trials with potential therapeutic breakthroughs, highlighting their strategic focus on oncology and rare diseases.
Boeing's Q3 loss and 777X delay contrasted with Airbus' strong quarter, highlighting the industry's uneven recovery.